Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines for cardiovascular, anti-diabetic, antineoplastic, and orthopedic therapeutic in China. It offers cardiovascular and cerebrovascular products, such as allisartan isoproxil, benazepril hydrochloride, desloratadine, and clopidogrel bisulfate tablets, as well as bivalirudin and pamidronate disodium injections; recombinant SeV-hFGF2/dF Injection for the treatment of diabetic foot disease; and anti-tumor and orthopedics medicines. The company also provides anti-infection products comprising cefonicid sodium, ceftazidime, ceftriaxone sodium, cefonicid sodium, cefminox sodium, cefuroxime sodium, cefepime hydrochloride, and cefodizime sodium injections, as well as azithromycin dispersible and levetiracetam tablets. In addition, it offers biotechnological drugs, such as recombinant protein and monoclonal antibody drugs. Further, the company is involved in import, licensing-in, and licensing-out medicines for Europe markets. The company was founded in 1998 and is headquartered in Shenzhen, China.
Shenzhenlubris Pharmaceuticals Dividend Announcement
• Shenzhenlubris Pharmaceuticals announced a annually dividend of ¥0.50 per ordinary share which will be made payable on 2024-06-19. Ex dividend date: 2024-06-19
• Shenzhenlubris Pharmaceuticals annual dividend for 2024 was ¥0.50
• Shenzhenlubris Pharmaceuticals annual dividend for 2023 was ¥0.50
• Shenzhenlubris Pharmaceuticals's trailing twelve-month (TTM) dividend yield is 1.5%
• Shenzhenlubris Pharmaceuticals's payout ratio for the trailing twelve months (TTM) is 178.78%
Shenzhenlubris Pharmaceuticals Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-06-19 | ¥0.50 | annually | 2024-06-19 |
2023-05-09 | ¥0.50 | annually | 2023-05-09 |
2022-04-27 | ¥0.40 | annually | 2022-04-27 |
2020-05-20 | ¥0.50 | annually | 2020-05-20 |
2019-04-16 | ¥0.80 | annually | 2019-04-16 |
2018-05-04 | ¥0.80 | annually | 2018-05-04 |
2017-05-12 | ¥0.70 | annually | 2017-05-12 |
2016-05-03 | ¥0.60 | annually | |
2015-04-24 | ¥0.70 | annually | |
2014-05-07 | ¥0.60 | annually | |
2013-05-09 | ¥0.70 | annually | |
2012-05-04 | ¥0.45 | annually |
Shenzhenlubris Pharmaceuticals Dividend per year
Shenzhenlubris Pharmaceuticals Dividend growth
Shenzhenlubris Pharmaceuticals Dividend Yield
Shenzhenlubris Pharmaceuticals current trailing twelve-month (TTM) dividend yield is 1.5%. Interested in purchasing Shenzhenlubris Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:
Shenzhenlubris Pharmaceuticals Financial Ratios
Shenzhenlubris Pharmaceuticals Dividend FAQ
Other factors to consider when evaluating Shenzhenlubris Pharmaceuticals as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Shenzhenlubris Pharmaceuticals stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Shenzhenlubris Pharmaceuticals's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Shenzhenlubris Pharmaceuticals publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Shenzhenlubris Pharmaceuticals distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Shenzhenlubris Pharmaceuticals are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Shenzhenlubris Pharmaceuticals sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Shenzhenlubris Pharmaceuticals distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Shenzhenlubris Pharmaceuticals declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Shenzhenlubris Pharmaceuticals's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Shenzhenlubris Pharmaceuticals's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.